USA - NASDAQ:SNOA - US83558L3033 - Common Stock
The current stock price of SNOA is 3.52 USD. In the past month the price decreased by -8.12%. In the past year, price increased by 27.02%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.04 | 979.10B | ||
| JNJ | JOHNSON & JOHNSON | 19.22 | 480.56B | ||
| MRK | MERCK & CO. INC. | 10.95 | 240.92B | ||
| PFE | PFIZER INC | 7.95 | 144.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.19 | 96.03B | ||
| ZTS | ZOETIS INC | 18.65 | 52.41B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.6 | 23.02B | ||
| VTRS | VIATRIS INC | 4.62 | 12.54B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.36 | 10.66B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.41B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.06B |
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
SONOMA PHARMACEUTICALS INC
5445 Conestoga Court, Suite 150
Boulder COLORADO 30189 US
CEO: Amy Trombly
Employees: 168
Phone: 18007599305
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
The current stock price of SNOA is 3.52 USD. The price decreased by -2.76% in the last trading session.
SNOA does not pay a dividend.
SNOA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
7 analysts have analysed SNOA and the average price target is 15.1 USD. This implies a price increase of 328.86% is expected in the next year compared to the current price of 3.52.
SONOMA PHARMACEUTICALS INC (SNOA) has a market capitalization of 5.81M USD. This makes SNOA a Nano Cap stock.
SONOMA PHARMACEUTICALS INC (SNOA) will report earnings on 2026-02-03, after the market close.
ChartMill assigns a technical rating of 1 / 10 to SNOA. When comparing the yearly performance of all stocks, SNOA turns out to be only a medium performer in the overall market: it outperformed 46.11% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to SNOA. The financial health of SNOA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months SNOA reported a non-GAAP Earnings per Share(EPS) of -2.2. The EPS increased by 55.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.11% | ||
| ROE | -91.87% | ||
| Debt/Equity | 0.01 |
7 analysts have analysed SNOA and the average price target is 15.1 USD. This implies a price increase of 328.86% is expected in the next year compared to the current price of 3.52.
For the next year, analysts expect an EPS growth of -96.42% and a revenue growth 11.38% for SNOA